Zoetis (ZTS)

Executive Summary

Zoetis Inc. (NYSE: ZTS) is the world's largest animal health company, spun off from Pfizer in 2013. It develops, manufactures, and commercializes a broad portfolio of medicines, vaccines, diagnostics, and services for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). With a presence in over 100 countries, Zoetis leverages its scale and R&D capabilities to address key therapeutic areas such as parasiticides, vaccines, anti-infectives, and dermatology. The company's business model centers on supporting veterinarians, livestock producers, and pet owners, linking animal health to broader outcomes in food security and the human-animal bond. Zoetis consistently generates strong revenue growth and margins, driven by its innovative pipeline and market leadership in both segments. The company's financial stability and recurring demand for animal health products underpin its position as a core holding in the biotech and healthcare sectors.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of new flea/tick oral treatment for dogs (next-gen isoxazoline)80% success
• Q4 2026Launch of poultry vaccine for avian influenza (revenue catalyst from emerging markets)70% success
• TBDPositive Phase 3 data for monoclonal antibody therapy for feline chronic kidney disease60% success